IL26 and neoplasm: Since granulocyte levels in the TME of hIL-26Tg mice treated with gefitinib were increased (Fig. 6G and Supplementary Fig. S13E), further studies are needed to clarify whether IL-26 affects the production of inflammatory cytokines from immune cells infiltrating the TME of TNBC treated with gefitinib, and whether these effects of IL-26 influence tumor growth or metastasis of TNBC in our in vivo model.